Shorter TB treatment regimens should be safer as well-Reference-Cited by-同舟云学术

Shorter TB treatment regimens should be safer as well

Published:2023-09-21 Issue:3 Volume:13 Page:104-106
ISSN:2220-8372
Container-title:Public Health Action
language:en
Short-container-title:public health action

Author:

Rucsineanu O.¹,Agbassi P.²,Herrera R.²,Low M.³,McKenna L.⁴,Stillo J.⁵,Winarni P.²,Acharya A.⁶,Sari A. H.²

Affiliation:

1. Moldova National Association of Tuberculosis Patients “SMIT” (Society of Moldova against Tuberculosis), Balti, Moldova, Global TB Community Advisory Board, New York, NY, USA

2. Global TB Community Advisory Board, New York, NY, USA

3. Department of Computer Science, University of Cape Town, Cape Town, South Africa

4. Global TB Community Advisory Board, New York, NY, USA, Treatment Action Group, New York, NY, USA

5. Global TB Community Advisory Board, New York, NY, USA, Department of Anthropology, Wayne State University, Detroit, MI, USA

6. Independent Consultant, Mumbai, India

Abstract

Most ongoing and planned TB therapeutic trials are focused on shortening the duration of treatment while giving less consideration to other aspects of TB care that are important to people with TB. Here we argue that other variables besides duration of TB treatment should also be considered when developing new TB treatment regimens, including drug toxicity, time spent in monitoring and overall quality of life while on therapy. We examine the specific use of linezolid in treatment-shortening trials for drug-susceptible TB and propose additional endpoints that should be prioritised in TB treatment studies.

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference4 articles.

1. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254

2. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding evidence for shortened treatment of latent tuberculosis infection: progress, not perfection;Clinical Microbiology and Infection;2024-08

2. Research on the treatment of rifampin-susceptible tuberculosis—Time for a new approach;PLOS Medicine;2024-07-25

3. High-dose rifampicin to treat tuberculosis infection: potential and pitfalls;The Lancet Respiratory Medicine;2024-06

4. Economic aspects of shortening the duration of tuberculosis treatment;The Lancet Global Health;2024-06